July 15, 2026 · Form 4 insider transaction
ADAR1 Capital Management, LLC bought 1,000 shares of InMed Pharmaceuticals Inc. at $1.55 per share, a transaction worth $1.6K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.
The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.; For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.